Diglycidic ether derivative therapeutics and methods for their use
This invention provides compound having a structure of Formula I or Formula II Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
1. A compound having the following structure:
2. A compound having the following structure:
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, diluent or combination thereof and a compound having the following structure:
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, diluent or combination thereof and a compound having the following structure:
5. A method of inhibiting androgen receptor activity, the method comprising administering the pharmaceutical composition of claim 3 to a subject in need thereof.
6. The method of claim 5 , wherein the inhibiting androgen receptor activity is for the treatment of one or more of the following: prostate cancer, breast cancer, ovarian cancer and endometrial cancer.
7. The method of claim 6 , wherein the inhibiting androgen receptor activity is for the treatment of prostate cancer.
8. The method of claim 7 , wherein the prostate cancer is castration resistant prostate cancer.
9. The method of claim 7 , wherein the prostate cancer is androgen-dependent prostate cancer.
10. A method of inhibiting androgen receptor activity, the method comprising administering the pharmaceutical composition of claim 4 to a subject in need thereof.
11. The method of claim 10 , wherein the inhibiting androgen receptor activity is for the treatment of one or more of the following: prostate cancer, breast cancer, ovarian cancer and endometrial cancer.
12. The method of claim 11 , wherein the inhibiting androgen receptor activity is for the treatment of prostate cancer.
13. The method of claim 12 , wherein the prostate cancer is castration resistant prostate cancer.
14. The method of claim 12 , wherein the prostate cancer is androgen-dependent prostate cancer.